Objective: To design, develop, and evaluate an evidence-based decision aid (DA) for patients with an asymptomatic abdominal aortic aneurysm (AAA) to inform them about the pros and cons of their treatment options (ie, surgery or watchful observation) and to help them make a shared decision. Methods: A multidisciplinary team defi ned criteria for the desired DA as to design, medical content and functionality, particularly for elderly users. Development was according to the international standard (IPDAS). Fifteen patients with an AAA, who were either treated or not yet treated, evaluated the tool. Results: A DA was developed to offer information about the disease, the risks and benefi ts of surgical treatment and watchful observation, and the individual possibilities and threats based on the patient's aneurysm diameter and risk profi le. The DA was improved and judged favorably by physicians and patients. Conclusion: This evidence-based DA for AAA patients, developed according to IPDAS criteria, is likely to be a simple, user-friendly tool to offer patients evidence-based information about the pros and cons of treatment options for AAA, to improve patients' understanding of the disease and treatment options, and may support decision making based on individual values.
Introduction
A decision aid (DA) is a tool to outline treatment options, to explore patient preferences and values, and to help patients in shared decision making. Such DAs have been developed over the years for a wide range of (mainly malignant) conditions as an adjunct to physicians' counseling. Its ultimate goal is to facilitate shared decision making and to increase quality of patient care (Molenaar et al 2001; Ruland 2004; Whelan et al 2004; Holmes-Rover et al 2005) . DAs comprise visual, graphic, or video-assisted illustrations of the risks and benefi ts involved. DAs were found to perform better in terms of decreasing decisional confl ict related to feeling informed, increasing knowledge and realistic expectations, increasing active participation in preference-sensitive decision making, and reducing the proportion of patients who remained undecided post intervention (O'Connor et al 2003; Timmermans et al 2004) .
An aneurysm of the abdominal aorta (AAA) is a local dilatation of the main abdominal artery which can be relatively small or huge. Approximately 75% of these AAAs are asymptomatic and are found coincidentally during physical examination or by ultrasonography or CT scanning (Lin and Lumsden 2003) . The prevalence is estimated to range between 1.7% and 6% in the elderly, primarily male, population (Drury et al 2005) . Patients with an AAA may never suffer from it, yet only 20% of them will survive an unexpected rupture of their aneurysm.
Surgery of an AAA should prevent rupture of the aneurysm, but may also induce complications and premature death due to the very procedure. Key issues in decisionmaking are the size of the aneurysm, which is related to risk of aneurysm rupture, and the risk of surgical complications as a result of advanced age or serious (cardiovascular) comorbidity (Lovegrove et al 2008) . Hence, patients with small aneurysms (Ͻ5.5 cm in diameter) are considered not to require surgery, but are usually managed by means of watchful observation with regular ultrasonography (UKSAT 2002) . For larger aneurysms, surgery is commonly advised and applied if the risk of complications is considered acceptable.
As the disorder per se does not necessarily lead to disease, the treating vascular surgeon and the patient face the dilemma of weighing the risk of rupture of the AAA during watchful observation against the risk of complications of surgery. As there is no single preferred treatment for these patients, their treatment preference plays a crucial role in the fi nal decision to arrive at 'shared decision-making' (Charles et al 1999) . Whenever such preference-sensitive decisions are to be made, decision-supportive interventions appear to be useful to help patients make an informed choice and to standardize the information given.
The aim of this project was to design and develop a DA for patients with an asymptomatic AAA to supply patients with information as to the pros and cons of the various treatment options, presented in a structured and easily accessible manner, eventually to facilitate well-informed and satisfactory decision making.
Methods
The DA was designed at the Academic Medical Center, Amsterdam, The Netherlands. Because this study focused on the development of a DA, and no intervention was performed that might infl uence the treatment of patients with an AAA, approval of the Hospital Ethics Advisory Board was waived. No commercial sponsoring was obtained.
The development of the DA was planned in fi ve stages: 1) composing a multidisciplinary development and advisory team, 2) defi ning the requirements of the desired DA, 3) obtaining the available evidence on the natural history, treatment, and complications of AAA, 4) designing and creating the DA, and fi nally 5) testing, adjusting, and evaluating the DA. (Elwyn et al 2006) .
• It should provide (references to) the best available, upto-date evidence from the medical literature to underpin the information given about all treatment options.
Stage 3: Included evidence
Data on rupture risk and benefi cial or harmful treatment effects were based on evidence from the literature searched from major medical databases (by AMK), such as PubMed and the Cochrane Library up to March 1, 2008. Accuracy of data extraction was checked by our group of vascular surgeons. From these data, overall estimates of survival, risks, and complications for the various treatment options were derived to be incorporated in the DA (Greenhalgh et al 2004; UKSAT 1998; DREAM 2005; Baas et al 2008) .
The indication for and prognosis after the various treatment options is known to be infl uenced by the comorbidity of the patient (Hirsch et al 2006) . A history of renal insuffi ciency and vascular comorbidity increases the risk of postoperative complications in AAA patients. To quantify this risk, the Glasgow Aneurysm Score (GAS) has been developed, which is a risk score calculated from the patient's age, kidney function, and history of cerebrovascular disease (Biancari et al 2003 (Biancari et al , 2008 ). This GAS is now a commonly used and validated prediction rule to help surgeons in decision making in AAA patients (Hirzalla et al 2006) .
Stage 4: Format, design, and creation of the DA Considering the high age and possible ignorance regarding the use of computers of the DA's target patients, we contemplated whether the optimum DA should be in a written or digital form. We initially aimed at producing a DA that would provide information tailored to the patient's condition and that would also allow us to record the parts of information that would be accessed and appreciated most by the patients. We therefore opted for a digital format for the DA, in which these data could be automatically recorded into log fi les. Moreover, several graphical images could be included to depict the risks and benefi ts involved in the different treatment options. Although it has been shown that graphical presentation of numerical data helps understanding such risks (Stiggelbout et al 1997) , a wide range of graphical presentation forms is available, but it is still unclear which one is most effective to convey the information and which of these patients prefer most.
The choice for a digital DA entailed designing a userfriendly, mouse-driven application, in which the patient would be guided through simple clicks along a preferential information route tailored to the patient's clinical situation. This situation would be determined by the patient's GAS and aneurysm diameter, to be entered at the beginning of the DA. If desired, however, the patient should be able to access the information regarding any of the other treatment options.
Stage 5: DA testing and evaluation
The pilot version of the DA was tested by four vascular surgeons, mainly for its medical content, and by four elderly subjects, for its usefulness and user-friendliness.
Based on their suggestions, the pilot version of the DA was improved and presented to a group of 15 former and actual AAA patients to evaluate comprehensibility and userfriendliness more formally. These patients were invited via the Dutch Society of Vascular Patients. A patient sample was composed varying in age, gender, computer profi ciency, education level, place of residence, and previous AAA treatment. They received the DA via email or were visited personally by the investigator (AMK), and were asked to fi ll in a short questionnaire about the DA (Table 2) .
Results
Starting April 2007, the pilot version was designed as a Powerpoint presentation (Microsoft Offi ce 2003; Microsoft Corp., Redmond, WA). This comprised a total of 170 pages ('slides') and offers general information as to the disorder, the possible treatment options, and the opportunity to balance the risks involved.
Users can thumb through the DA and choose information tailored to their individual physical condition. For this purpose, action buttons on 'crossroads' pages enable to skip the next pages on topics the users consider less relevant. In addition, the user can be directed to information pertinent to the patient by choosing their aneurysm diameter (less than or above 5.5 cm), possible treatment options (open or endovascular aneurysm repair or watchful observation) as suggested by their surgeon or the patient's personal GAS score. To prevent from 'getting lost' in the program, a 'breadcrumb trail' was added to indicate the progress of, and position in, the program. To further comply with the IPDAS criteria, we added the following items: date of last update, a statement the developers of the DA would not benefi t from whichever choice the patient would make based on the DA, and references to the (level of) evidence for the various bits of information given in the DA. In addition we elaborated the section in which patients can consider their own situation as to treatment options, risks and anxiety. The fi nal pilot version of the DA, developed during a period of three months, complied with 33 out of 40 IPDAS criteria.
Some of the pages in the DA are presented in Figures 1-4 . They illustrate the information supplied on the disease itself (Figure 1 ), the risk of rupture presented as a Figure ( An widening of the aorta of more than 3 cms, or more than 1.5 times its original diameter, is called an aneurysm.
Slowly wider
The widening of the aorta is a gradual process. The growth rate may vary, but is usually a few millimetres per year.
Continue 5 start

AAA Decision Aid. © 2008 Dept. of Quality Assurance & Process Innovation, Section Evidence-Based Practice
Normal aorta
Aorta with a large aneurysm This risk increases considerably when the aneurysm grows to more than 5 cms in diameter.
If you click the speaker icon, the figure is explained verbally.
(Switch on your computer loudspeaker). o After surgery you will need a recovery period of about 3 to 6 months to return to normal life. If you undergo the operation via the groin, the recovery period is shorter (about 1 to 3 months).
Benefit o You will avoid the risk of dying or (serious) complications due to the operation o You do not have to recover from an operation. This would require a recovery period of about 3 to 6 months to return to normal life. If you were to undergo the operation via the groin, the recovery period would be shorter (about 1 to 3 months).
Harm
o You still run the risk of a rupture of the aneurysm and of dying from it. This may frighten you and your relatives. o You must visit your surgeon once a year to check the growth of the aneurysm.
Endovascular surgery Watchful observation
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At this point you have been informed about:
o The aneurysm of the abdominal aorta and the possible treatment options. o Your personal risk of a rupture of the aneurysm (from which most people die). o Your personal risk of dying or suffering (serious) complications due to the operation. o Important things to consider before you can make your decision
It is now up to you, and your surgeon and relatives, to decide which considerations are deciding. , and 'feeling better informed' 68 (IQR 50-90). The vast majority of patients stated the DA offered additional value in their decision making, and all but one patient found the fi gures on possible risks clarifying rather than frightening. Every type of graphical representation was valued most by at least some of the patients. No clear differences were observed between patients who had and those who had not yet undergone surgical treatment for their AAA.
Finally, a linguistic check was performed (SM) to ensure the use of plain language and easy interpretation of the DA. The program, now available on CDROM, was also equipped with the possibility to print concise information in the form of a brochure the patient can take home. The DA has been registered in the Cochrane Decision Aid Library Inventory (DALI) of the Ottawa Health Decision Centre (see https:// decisionaid.ohri.ca/DALI).
Discussion
In this paper the development of the fi rst DA regarding treatment options for patients with an asymptomatic AAA is described. This computer-based DA is evidence-based, is developed according to the IPDAS criteria, and is approved by the Dutch Society of Vascular Patients.
The development of this DA was similar to those in other medical realms, eg, cancer of the breast, prostate, or lungs (Molenaar et al 2001; Feldman-Stewart and Brundage 2004; Holmes-Rovner 2005; Chiew et al 2007) , in which patients may be overwhelmed by a potentially life-threatening diagnosis and at the same time are invited to participate in treatment decision making. On the other hand, this DA differs in that it focuses on an asymptomatic disorder that will remain without consequences until either rupture or surgical treatment occurs. In addition, this DA may offer surgeons a tool to share necessary information in an evidence-based, standardized format.
In only one RCT the benefi ts of a comprehensive, highly individualized, evidence-based brochure for asymptomatic AAA patients based on information by way of Markov analysis have been studied. The highly individualized information was found to be dissatisfying and impractical (Molewijk 2006) . Therefore, the information offered in this DA was mainly on headlines rather than focusing only on the individual situation of each patient (Feldman-Stewart and Brundage 2004) . However, as risk of rupture strongly correlates to the size of the aneurysm, and surgical risk considerably increases with the presence of comorbidity, it was thought to be necessary to tailor information in the DA to these two factors in order for the DA to be a useful adjuvant in the communication between patient and surgeon. In addition, the IPDAS criteria also describe "the possibility to view probabilities based on the patient's own situation" as one of the quality criteria.
This DA was made in accordance with the vast majority of IPDAS criteria. Although these criteria are not yet commonly applied, they should improve the value of DAs to let patients better understand their own condition, to reduce decisional confl ict, and to help them make an informed choice (O'Connor et al 2007) . The debate is ongoing about the value of DAs to improve clinical decision making (Holmes-Rovner et al 2007). DAs did not appear to outperform comparative strategies in affecting patient satisfaction with decision making, anxiety, and health outcomes (O'Connor et al 2003) . Furthermore, DAs can only be developed if evidence is available in suffi cient amounts to underpin the information supplied for the various treatment alternatives.
The initial version of this decision support had limitations as to the complexity of the individual risk information, which was dissatisfying for the patient. After adjustments, appraisal by AAA patients showed that this DA was considered userfriendly, of additional value, and improved understanding. As intended, the DA was found to be not simply an informative 'digital brochure' containing basic information about treatment options, but rather seemed to be a possibly useful tool to actually help patients decide upon their optimum treatment choice.
We actually do not yet know whether the DA really offers more (useful) information than what the vascular surgeons already explain to the patient and whether it is also capable of increasing patients' knowledge and subsequently reducing patients' decisional confl ict regarding their treatment choice. Ultimately, it might also improve satisfaction, quality of life,
